NSPR · InspireMD, Inc.
AI read · Good for NSPR
The AI's read
This gives InspireMD a route back to U.S. sales and access to more procedures. The company expects sales to begin in the fourth quarter, so the added reach has not yet appeared in reported U.S. sales. International revenue also rose 9% from the same quarter last year. A separate CAS version still needs final testing and another FDA filing before a possible 2027 relaunch. InspireMD reported $19.2 million in cash and marketable securities, but gave no earlier figure or spending rate.